Substantial, randomized, and controlled studies of HER2‐targeted therapies have been advantageous for patients with HER2‐positive gastroesophageal adenocarcinoma and breast cancer, as HER2 overexpression and amplification is more frequent in these cancers. The gene discussed is ERBB2; the disease is cancer.